Detailed phase 3 data show retatrutide lowered body weight and A1C over 80 weeks for patients with diabetes and obesity.

In a rapidly evolving diabetes and obesity management landscape, Brian Smith, PharmD, discusses approaches that are helping patients maximize their outcomes on GLP-1 therapy.

In this episode, our hosts examine the expanding role of incretin therapies in children and adolescents with obesity and type 2 diabetes.

GLP-1 adherence requires integrated care teams, administrative technology, and proactive clinical support to tackle complex challenges.

Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.

A claims analysis of 2031 patients aged 10 to 17 years found that nutrition counseling was infrequent and often began months after treatment started.

Diabetes medication experts focus on practical access and pharmacist counseling considerations for adults on obesity medication.

Pharmacists can improve cardiometabolic adherence by easing adverse effects, simplifying regimens, tackling costs, and synchronizing refills.